Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 8/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | GFER | P55789 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | AHR | P35869 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | BRPF1 | P55201 | 6/20 | 0.58 |
| ▸ | BRD4 | O60885 | 4/20 | 0.58 |
| ▸ | BRD1 | O95696 | 3/20 | 0.58 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.58 |
| ▸ | BRPF3 | Q9ULD4 | 2/20 | 0.58 |
| ▸ | TAF1 | P21675 | 1/20 | 0.58 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.58 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339593 | 0.90 | BRPF1 (0.60) | RXFP1MAPTRAB9ASMN1; SMN2GFER | |
| SCHEMBL339940 | 0.90 | RXFP1 (0.62) | RXFP1MAPTRAB9ASMN1; SMN2GFER | |
| SCHEMBL341092 | 0.87 | KMT2A (0.57) | RXFP1MAPTRAB9ASMN1; SMN2GFER | |
| SCHEMBL339293 | 0.86 | LRRK2 (0.63) | RXFP1MAPTRAB9ASMN1; SMN2GFER | |
| SCHEMBL15528460 | 0.84 | RXFP1 (1.00) | RXFP1MAPTRAB9ASMN1; SMN2GFER | |
| SCHEMBL21682949 | 0.81 | BRPF1 (0.61) | RXFP1MAPTRAB9ASMN1; SMN2GFER | |
| SCHEMBL340604 | 0.81 | RAB9A (0.56) | RXFP1MAPTRAB9ASMN1; SMN2GFER | |
| SCHEMBL340622 | 0.81 | MAPT (0.68) | MAPTRAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL341059 | 0.79 | MEN1 (0.61) | MAPTRAB9ASMN1; SMN2NPC1BRD4 | |
| SCHEMBL21701459 | 0.79 | RXFP1 (0.54) | RXFP1MAPTRAB9ASMN1; SMN2GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112348-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2017-01-04 | — | — | EP | disclosed |
| EP-2593435-B1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | TAIRX INC (TW) | 2016-09-07 | — | — | EP | disclosed |
| CN-103347859-B | Synthesis and Anticancer Activity of Aryl and Heteroaryl Quinoline Derivatives | EFFICIENT PHARMA MANAGEMENT CORP. (CN) | 2015-12-02 | — | — | CN | disclosed |
| CN-103347859-A | Synthesis and Anticancer Activity of Aryl and Heteroaryl Quinoline Derivatives | EFFICIENT PHARMA MAN CORP | 2013-10-09 | — | — | CN | disclosed |
| US-8524740-B2 | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives | TAIRX, INC. (TW) | 2013-09-03 | — | — | US | disclosed |
| EP-2593435-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2013-05-22 | — | — | EP | disclosed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009519-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | EFFICIENT PHARMA MANAGEMENT CORP. (TW) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | SLC22A8, ABCC8, CYP2C8 | RXFP1 3003/4885MAPT 4760/4885RAB9A 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.